These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8257144)

  • 21. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
    Gotfried MH; Danziger LH; Rodvold KA
    Chest; 2001 Apr; 119(4):1114-22. PubMed ID: 11296178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes.
    Beck R; van Keyserlingk J; Fischer U; Guthoff R; Drewelow B
    Graefes Arch Clin Exp Ophthalmol; 1999 Feb; 237(2):89-92. PubMed ID: 9987622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally.
    Bitar N; Claes R; Van der Auwera P
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1686-90. PubMed ID: 2589841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC; Smith JT
    Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
    Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Serum pharmacokinetics and in vitro antibacterial activity of pefloxacin, ofloxacin and ciprofloxacin].
    Nordmann P; Jarlier V
    Presse Med; 1990 Sep 1-8; 19(28):1321-5. PubMed ID: 2145562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 1999 Jan; 43(1):79-86. PubMed ID: 10381104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
    Chalkley LJ; Koornhof HJ
    Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution.
    Colino CI; García Turiño A; Sanchez Navarro A; Lanao JM
    Biopharm Drug Dispos; 1998 Mar; 19(2):71-7. PubMed ID: 9580344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
    McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics of ofloxacin and ciprofloxacin.
    Wolfson JS; Hooper DC
    Am J Med; 1989 Dec; 87(6C):31S-36S. PubMed ID: 2690617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():73-9. PubMed ID: 3182465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.